Literature DB >> 10369862

A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2.

U R Monani1, C L Lorson, D W Parsons, T W Prior, E J Androphy, A H Burghes, J D McPherson.   

Abstract

Spinal muscular atrophy (SMA) is a recessive disorder characterized by loss of motor neurons in the spinal cord. It is caused by mutations in the telomeric survival motor neuron 1 ( SMN1 ) gene. Alterations within an almost identical copy gene, the centromeric survival motor neuron 2 ( SMN2 ) gene produce no known phenotypic effect. The exons of the two genes differ by just two nucleotides, neither of which alters the encoded amino acids. At the genomic level, only five nucleotides that differentiate the two genes from one another have been reported. The entire genomic sequence of the two genes has not been determined. Thus, differences which might explain why SMN1 is the SMA gene are not readily apparent. In this study, we have completely sequenced and compared genomic clones containing the SMN genes. The two genes show striking similarity, with the homology being unprecedented between two different yet functional genes. The only critical difference in an approximately 32 kb region between the two SMN genes is the C->T base change 6 bp inside exon 7. This alteration but not other variations in the SMN genes affects the splicing pattern of the genes. The majority of the transcript from the SMN1 locus is full length, whereas the majority of the transcript produced by the SMN2 locus lacks exon 7. We suggest that the exon 7 nucleotide change affects the activity of an exon splice enhancer. In SMA patients, the loss of SMN1 but the presence of SMN2 results in low levels of full-length SMN transcript and therefore low SMN protein levels which causes SMA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369862     DOI: 10.1093/hmg/8.7.1177

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  396 in total

1.  SMN dosage analysis and risk assessment for spinal muscular atrophy.

Authors:  Shuji Ogino; Robert B Wilson
Journal:  Am J Hum Genet       Date:  2002-06       Impact factor: 11.025

2.  IPLEX administration improves motor neuron survival and ameliorates motor functions in a severe mouse model of spinal muscular atrophy.

Authors:  Michela Murdocca; Arianna Malgieri; Andrea Luchetti; Luciano Saieva; Gabriella Dobrowolny; Elvira de Leonibus; Antonio Filareto; Maria Chiara Quitadamo; Giuseppe Novelli; Antonio Musarò; Federica Sangiuolo
Journal:  Mol Med       Date:  2012-09-25       Impact factor: 6.354

3.  Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2).

Authors:  Y Hofmann; C L Lorson; S Stamm; E J Androphy; B Wirth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

4.  In vivo selection reveals combinatorial controls that define a critical exon in the spinal muscular atrophy genes.

Authors:  Natalia N Singh; Elliot J Androphy; Ravindra N Singh
Journal:  RNA       Date:  2004-08       Impact factor: 4.942

5.  Carrier incidence for spinal muscular atrophy in southern Chinese.

Authors:  Vivian Chan; Ben Yip; Irene Yam; Patrick Au; Che-Kit Lin; Virginia Wong; Tai-Kwong Chan
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

6.  Failure of lower motor neuron radial outgrowth precedes retrograde degeneration in a feline model of spinal muscular atrophy.

Authors:  Erin N Wakeling; Béatrice Joussemet; Patrick Costiou; Dominique Fanuel; Philippe Moullier; Martine Barkats; John C Fyfe
Journal:  J Comp Neurol       Date:  2012-06-01       Impact factor: 3.215

7.  Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.

Authors:  Ferrill F Rose; Virginia B Mattis; Hansjörg Rindt; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2008-12-12       Impact factor: 6.150

8.  Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts.

Authors:  Leigh A Skordis; Matthew G Dunckley; Baigong Yue; Ian C Eperon; Francesco Muntoni
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

Review 9.  Spinal muscular atrophy.

Authors:  Susan T Iannaccone; Stephen A Smith; Louise R Simard
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

Review 10.  Targeting RNA in mammalian systems with small molecules.

Authors:  Anita Donlic; Amanda E Hargrove
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-05-03       Impact factor: 9.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.